|
Oct 2
|
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
|
|
Sep 30
|
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
|
|
Aug 5
|
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
|
|
Jul 30
|
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
|
|
May 30
|
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
|
|
Feb 1
|
Clarion Clinics Open for Psychedelic-Assisted Treatments
|
|
Dec 21
|
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia
|
|
Dec 6
|
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
|
|
Nov 29
|
Incannex Healthcare Announces Completion of its Redomiciliation to the United States
|
|
Jun 23
|
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
|
|
May 3
|
Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
|
|
May 2
|
Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
|